Cargando…

A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer

BACKGROUND: Docetaxel (D) or secondary hormonal therapy (SHT) each combined with androgen deprivation therapy (ADT) represent possible treatment options in males with metastasized hormone‐sensitive prostate cancer (mHSPC). Real‐world data comparing different protocols are lacking yet. Thus, our obje...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsaur, Igor, Heidegger, Isabel, Bektic, Jasmin, Kafka, Mona, van den Bergh, Roderick C. N., Hunting, Jarmo C. B., Thomas, Anita, Brandt, Maximilian P., Höfner, Thomas, Debedde, Eliott, Thibault, Constance, Ermacora, Paola, Zattoni, Fabio, Foti, Silvia, Kretschmer, Alexander, Ploussard, Guillaume, Rodler, Severin, von Amsberg, Gunhild, Tilki, Derya, Surcel, Christian, Rosenzweig, Barak, Gadot, Moran, Gandaglia, Giorgio, Dotzauer, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446402/
https://www.ncbi.nlm.nih.gov/pubmed/34374489
http://dx.doi.org/10.1002/cam4.4184
_version_ 1784568864127844352
author Tsaur, Igor
Heidegger, Isabel
Bektic, Jasmin
Kafka, Mona
van den Bergh, Roderick C. N.
Hunting, Jarmo C. B.
Thomas, Anita
Brandt, Maximilian P.
Höfner, Thomas
Debedde, Eliott
Thibault, Constance
Ermacora, Paola
Zattoni, Fabio
Foti, Silvia
Kretschmer, Alexander
Ploussard, Guillaume
Rodler, Severin
von Amsberg, Gunhild
Tilki, Derya
Surcel, Christian
Rosenzweig, Barak
Gadot, Moran
Gandaglia, Giorgio
Dotzauer, Robert
author_facet Tsaur, Igor
Heidegger, Isabel
Bektic, Jasmin
Kafka, Mona
van den Bergh, Roderick C. N.
Hunting, Jarmo C. B.
Thomas, Anita
Brandt, Maximilian P.
Höfner, Thomas
Debedde, Eliott
Thibault, Constance
Ermacora, Paola
Zattoni, Fabio
Foti, Silvia
Kretschmer, Alexander
Ploussard, Guillaume
Rodler, Severin
von Amsberg, Gunhild
Tilki, Derya
Surcel, Christian
Rosenzweig, Barak
Gadot, Moran
Gandaglia, Giorgio
Dotzauer, Robert
author_sort Tsaur, Igor
collection PubMed
description BACKGROUND: Docetaxel (D) or secondary hormonal therapy (SHT) each combined with androgen deprivation therapy (ADT) represent possible treatment options in males with metastasized hormone‐sensitive prostate cancer (mHSPC). Real‐world data comparing different protocols are lacking yet. Thus, our objective was to compare the efficacy and safety of abiraterone acetate (AA)+ADT versus D+ADT in mHSPC. METHODS: In a retrospective multicenter analysis including males with mHSPC treated with either of the aforementioned protocols, overall survival (OS), progression‐free survival 1 (PFS1), and progression‐free survival 2 (PFS2) were assessed for both cohorts. Median time to event was tested by Kaplan–Meier method and log‐rank test. The Cox‐proportional hazards model was used for univariate and multivariate regression analyses. RESULTS: Overall, 196 patients were included. The AA+ADT cohort had a longer PFS1 in the log‐rank testing (23 vs. 13 mos., p < 0.001), a longer PFS2 (48 vs. 33 mos., p = 0.006), and longer OS (80 vs. 61 mos., p = 0.040). In the multivariate analyses AA+ADT outperformed D+ADT in terms of PFS1 (HR = 0.34, 95% CI = 0.183–0.623; p = 0.001) and PFS2 (HR = 0.33 95% CI = 0.128–0.827; p = 0.018), respectively, while OS and toxicity rate were similar between both groups. CONCLUSIONS: AA+ADT is mainly associated with a similar efficacy and overall toxicity rate as D+ADT. Further prospective research is required for validation of the clinical value of the observed benefit of AA+ADT for progression‐free end‐points.
format Online
Article
Text
id pubmed-8446402
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84464022021-09-22 A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer Tsaur, Igor Heidegger, Isabel Bektic, Jasmin Kafka, Mona van den Bergh, Roderick C. N. Hunting, Jarmo C. B. Thomas, Anita Brandt, Maximilian P. Höfner, Thomas Debedde, Eliott Thibault, Constance Ermacora, Paola Zattoni, Fabio Foti, Silvia Kretschmer, Alexander Ploussard, Guillaume Rodler, Severin von Amsberg, Gunhild Tilki, Derya Surcel, Christian Rosenzweig, Barak Gadot, Moran Gandaglia, Giorgio Dotzauer, Robert Cancer Med Clinical Cancer Research BACKGROUND: Docetaxel (D) or secondary hormonal therapy (SHT) each combined with androgen deprivation therapy (ADT) represent possible treatment options in males with metastasized hormone‐sensitive prostate cancer (mHSPC). Real‐world data comparing different protocols are lacking yet. Thus, our objective was to compare the efficacy and safety of abiraterone acetate (AA)+ADT versus D+ADT in mHSPC. METHODS: In a retrospective multicenter analysis including males with mHSPC treated with either of the aforementioned protocols, overall survival (OS), progression‐free survival 1 (PFS1), and progression‐free survival 2 (PFS2) were assessed for both cohorts. Median time to event was tested by Kaplan–Meier method and log‐rank test. The Cox‐proportional hazards model was used for univariate and multivariate regression analyses. RESULTS: Overall, 196 patients were included. The AA+ADT cohort had a longer PFS1 in the log‐rank testing (23 vs. 13 mos., p < 0.001), a longer PFS2 (48 vs. 33 mos., p = 0.006), and longer OS (80 vs. 61 mos., p = 0.040). In the multivariate analyses AA+ADT outperformed D+ADT in terms of PFS1 (HR = 0.34, 95% CI = 0.183–0.623; p = 0.001) and PFS2 (HR = 0.33 95% CI = 0.128–0.827; p = 0.018), respectively, while OS and toxicity rate were similar between both groups. CONCLUSIONS: AA+ADT is mainly associated with a similar efficacy and overall toxicity rate as D+ADT. Further prospective research is required for validation of the clinical value of the observed benefit of AA+ADT for progression‐free end‐points. John Wiley and Sons Inc. 2021-08-10 /pmc/articles/PMC8446402/ /pubmed/34374489 http://dx.doi.org/10.1002/cam4.4184 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Tsaur, Igor
Heidegger, Isabel
Bektic, Jasmin
Kafka, Mona
van den Bergh, Roderick C. N.
Hunting, Jarmo C. B.
Thomas, Anita
Brandt, Maximilian P.
Höfner, Thomas
Debedde, Eliott
Thibault, Constance
Ermacora, Paola
Zattoni, Fabio
Foti, Silvia
Kretschmer, Alexander
Ploussard, Guillaume
Rodler, Severin
von Amsberg, Gunhild
Tilki, Derya
Surcel, Christian
Rosenzweig, Barak
Gadot, Moran
Gandaglia, Giorgio
Dotzauer, Robert
A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer
title A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer
title_full A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer
title_fullStr A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer
title_full_unstemmed A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer
title_short A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer
title_sort real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446402/
https://www.ncbi.nlm.nih.gov/pubmed/34374489
http://dx.doi.org/10.1002/cam4.4184
work_keys_str_mv AT tsaurigor arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT heideggerisabel arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT bekticjasmin arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT kafkamona arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT vandenberghroderickcn arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT huntingjarmocb arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT thomasanita arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT brandtmaximilianp arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT hofnerthomas arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT debeddeeliott arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT thibaultconstance arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT ermacorapaola arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT zattonifabio arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT fotisilvia arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT kretschmeralexander arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT ploussardguillaume arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT rodlerseverin arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT vonamsberggunhild arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT tilkiderya arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT surcelchristian arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT rosenzweigbarak arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT gadotmoran arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT gandagliagiorgio arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT dotzauerrobert arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT arealworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT tsaurigor realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT heideggerisabel realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT bekticjasmin realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT kafkamona realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT vandenberghroderickcn realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT huntingjarmocb realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT thomasanita realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT brandtmaximilianp realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT hofnerthomas realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT debeddeeliott realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT thibaultconstance realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT ermacorapaola realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT zattonifabio realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT fotisilvia realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT kretschmeralexander realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT ploussardguillaume realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT rodlerseverin realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT vonamsberggunhild realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT tilkiderya realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT surcelchristian realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT rosenzweigbarak realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT gadotmoran realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT gandagliagiorgio realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT dotzauerrobert realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer
AT realworldcomparisonofdocetaxelversusabirateroneacetateformetastatichormonesensitiveprostatecancer